Roche Stock Price, News & Analysis (OTCMKTS:RHHBY)

$29.62 -0.15 (-0.50 %)
(As of 02/22/2018 05:36 AM ET)
Previous Close$29.77
Today's Range$29.59 - $29.98
52-Week Range$28.48 - $36.82
Volume1.66 million shs
Average Volume2.11 million shs
Market Capitalization$207.06 billion
P/E Ratio22.10
Dividend Yield2.84%
Beta0.55

About Roche (OTCMKTS:RHHBY)

Roche logoRoche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Receive RHHBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RHHBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RHHBY
CUSIPN/A
Phone+41-9-732354295

Debt

Debt-to-Equity Ratio0.66%
Current Ratio1.29%
Quick Ratio0.92%

Price-To-Earnings

Trailing P/E Ratio22.1044776119403
Forward P/E Ratio13.84
P/E Growth1.85

Sales & Book Value

Annual Sales$54.15 billion
Price / Sales3.73
Cash Flow$1.76 per share
Price / Cash16.84
Book Value$3.93 per share
Price / Book7.54

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees94,052
Outstanding Shares6,815,420,000

Roche (OTCMKTS:RHHBY) Frequently Asked Questions

What is Roche's stock symbol?

Roche trades on the OTCMKTS under the ticker symbol "RHHBY."

Where is Roche's stock going? Where will Roche's stock price be in 2018?

11 Wall Street analysts have issued twelve-month price targets for Roche's stock. Their forecasts range from $38.00 to $38.00. On average, they expect Roche's share price to reach $38.00 in the next year. View Analyst Ratings for Roche.

Who are some of Roche's key competitors?

Who are Roche's key executives?

Roche's management team includes the folowing people:

  • Severin Schwan, Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director (Age 51)
  • Alan Hippe, Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer (Age 51)
  • Sophie Kornowski-Bonnet, Member of the Enlarged Corporate Executive Committee, Head Roche Partnering (Age 54)
  • Osamu Nagayama, Member of the Enlarged Corporate Executive Committee, Chairman and Chief Executive Officer Chugai (Age 70)
  • John C. Reed M.D., Ph.D., Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development (Age 60)
  • Michael David Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development (Age 60)
  • Cristina A. Wilbur, Member of the Executive Committee, Head Group Human Resources (Age 51)
  • Urs Jaisli, Chief Compliance Officer (Age 62)
  • Gottlieb A. Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors (Age 64)
  • Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications (Age 56)

Who owns Roche stock?

Roche's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.24%), Schafer Cullen Capital Management Inc. (0.04%), Bristol John W & Co. Inc. NY (0.03%), Capital Counsel LLC NY (0.02%), Riverbridge Partners LLC (0.01%) and Boston Common Asset Management LLC (0.00%). View Institutional Ownership Trends for Roche.

Who sold Roche stock? Who is selling Roche stock?

Roche's stock was sold by a variety of institutional investors in the last quarter, including Moody Lynn & Lieberson LLC, Capital Counsel LLC NY, Bristol John W & Co. Inc. NY, Riverbridge Partners LLC, Somerville Kurt F, Sterling Capital Management LLC, Gardiner Nancy B and Anderson Hoagland & Co.. View Insider Buying and Selling for Roche.

Who bought Roche stock? Who is buying Roche stock?

Roche's stock was purchased by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Douglass Winthrop Advisors LLC, Teachers Retirement System of The State of Kentucky, Delphi Management Inc. MA, Schafer Cullen Capital Management Inc., Puzo Michael J, FNY Partners Fund LP and North Star Asset Management Inc.. View Insider Buying and Selling for Roche.

How do I buy Roche stock?

Shares of Roche can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Roche's stock price today?

One share of Roche stock can currently be purchased for approximately $29.62.

How big of a company is Roche?

Roche has a market capitalization of $207.06 billion and generates $54.15 billion in revenue each year. The company earns $8.77 billion in net income (profit) each year or $1.34 on an earnings per share basis. Roche employs 94,052 workers across the globe.

How can I contact Roche?

Roche's mailing address is Grenzacherstr. 124, BASEL, 4058, Switzerland. The company can be reached via phone at +41-9-732354295 or via email at [email protected]


MarketBeat Community Rating for Roche (RHHBY)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  195
MarketBeat's community ratings are surveys of what our community members think about Roche and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Roche (OTCMKTS:RHHBY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.182.252.272.44
Ratings Breakdown: 2 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.00$38.00$38.00$38.00
Price Target Upside: 19.59% upside19.59% upside27.90% upside20.71% upside

Roche (OTCMKTS:RHHBY) Consensus Price Target History

Price Target History for Roche (OTCMKTS:RHHBY)

Roche (OTCMKTS:RHHBY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/15/2018Societe GeneraleDowngradeHold -> SellView Rating Details
12/29/2017JPMorgan Chase & Co.Reiterated RatingOverweight -> OverweightView Rating Details
12/7/2017Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
10/24/2017Berenberg BankDowngradeBuy -> HoldView Rating Details
10/18/2017CitigroupDowngradeBuy -> NeutralView Rating Details
9/26/2017BNP ParibasDowngradeNeutral -> UnderperformView Rating Details
9/19/2017CowenReiterated RatingBuy$38.00View Rating Details
7/26/2017Morgan StanleyReiterated RatingOverweight -> Equal WeightView Rating Details
7/7/2017Deutsche BankDowngradeBuy -> HoldView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldView Rating Details
3/7/2017BarclaysInitiated CoverageOverweightView Rating Details
2/19/2017Jefferies GroupReiterated RatingBuyView Rating Details
12/7/2016Sanford C. BernsteinReiterated RatingOverweightView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Earnings History for Roche (OTCMKTS:RHHBY)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Roche (OTCMKTS:RHHBY) Earnings Estimates

Current Year EPS Consensus Estimate: $2.14 EPS
Next Year EPS Consensus Estimate: $2.24 EPS

Dividends

Dividend History for Roche (OTCMKTS:RHHBY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Roche (OTCMKTS RHHBY)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Roche (OTCMKTS RHHBY) News Headlines

Source:
DateHeadline
Swiss pharma company Roche is buying Flatiron Health for $1.9 billionSwiss pharma company Roche is buying Flatiron Health for $1.9 billion
finance.yahoo.com - February 17 at 4:51 PM
Top VC deals: Roche acquires Flatiron, Harrys raises $112 million to go beyond shavingTop VC deals: Roche acquires Flatiron, Harry's raises $112 million to go beyond shaving
finance.yahoo.com - February 17 at 8:25 AM
Roche (RHHBY) to Acquire Flatiron Health for $1.9 BillionRoche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
www.zacks.com - February 16 at 8:30 AM
Roche to buy Flatiron Health for $1.9 blnRoche to buy Flatiron Health for $1.9 bln
finance.yahoo.com - February 16 at 8:30 AM
Alphabet-backed Flatiron Health is being acquired by RocheAlphabet-backed Flatiron Health is being acquired by Roche
finance.yahoo.com - February 16 at 8:30 AM
[$$] Roche to Acquire Healthcare-Software Company Flatiron for $1.9 Billion[$$] Roche to Acquire Healthcare-Software Company Flatiron for $1.9 Billion
finance.yahoo.com - February 16 at 8:30 AM
Roche to buy Flatiron Health for $1.9 billion to expand cancer care portfolioRoche to buy Flatiron Health for $1.9 billion to expand cancer care portfolio
finance.yahoo.com - February 15 at 5:10 PM
[$$] Roche to Acquire Flatiron Health for $1.9 Billion[$$] Roche to Acquire Flatiron Health for $1.9 Billion
finance.yahoo.com - February 15 at 5:10 PM
Roche to buy Flatiron Health for $1.9 bln to expand cancer care portfolioRoche to buy Flatiron Health for $1.9 bln to expand cancer care portfolio
finance.yahoo.com - February 15 at 5:10 PM
Where Pfizer’s Xeljanz Is Positioned for 2018Where Pfizer’s Xeljanz Is Positioned for 2018
finance.yahoo.com - February 15 at 8:02 AM
Roche Holding ADR (RHHBY) Presents At 15th Angiogenesis Meetinig 2018 - SlideshowRoche Holding ADR (RHHBY) Presents At 15th Angiogenesis Meetinig 2018 - Slideshow
seekingalpha.com - February 13 at 3:53 PM
Drug copies ready to take next bite out of Roches cancer salesDrug copies ready to take next bite out of Roche's cancer sales
finance.yahoo.com - February 13 at 3:53 PM
Roche Diagnostics recognizes Wisconsin Diagnostic Laboratories as Roche Molecular Center of ExcellenceRoche Diagnostics recognizes Wisconsin Diagnostic Laboratories as Roche Molecular Center of Excellence
finance.yahoo.com - February 13 at 9:51 AM
ImmunoMet Appoints Vincent J. ONeill, M.D., B.Sc., M.R.C.P, as Chief Medical Officer, and Allan L. Shaw as Chief Financial OfficerImmunoMet Appoints Vincent J. O'Neill, M.D., B.Sc., M.R.C.P, as Chief Medical Officer, and Allan L. Shaw as Chief Financial Officer
www.bizjournals.com - February 12 at 3:54 PM
Mavyret Is Expected to Boost AbbVie’s Hepatitis C Revenue in 2018Mavyret Is Expected to Boost AbbVie’s Hepatitis C Revenue in 2018
finance.yahoo.com - February 9 at 9:45 AM
Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?Will Prothena (PRTA) Disappoint Investors in Q4 Earnings?
finance.yahoo.com - February 9 at 9:45 AM
Roche wins UK watchdogs nod for lymphoma drug after initial snubRoche wins UK watchdog's nod for lymphoma drug after initial snub
finance.yahoo.com - February 9 at 9:45 AM
Roche Finance Europe BV -- Moodys upgrades Roche to Aa3; outlook stableRoche Finance Europe BV -- Moody's upgrades Roche to Aa3; outlook stable
finance.yahoo.com - February 8 at 3:51 PM
Roche notches fresh win amid crowd of immunotherapy cocktailsRoche notches fresh win amid crowd of immunotherapy cocktails
finance.yahoo.com - February 6 at 3:52 PM
Array melanoma drugs show significant survival vs Roche drug in studyArray melanoma drugs show significant survival vs Roche drug in study
finance.yahoo.com - February 6 at 9:41 AM
Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People With Advanced Kidney CancerPhase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People With Advanced Kidney Cancer
finance.yahoo.com - February 6 at 9:41 AM
3 Top Obesity-Drug Stocks to Consider Buying Now3 Top Obesity-Drug Stocks to Consider Buying Now
finance.yahoo.com - February 3 at 3:56 PM
Roche Holding Ltd. (RHHBY) Given Average Rating of "Hold" by BrokeragesRoche Holding Ltd. (RHHBY) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 3 at 1:44 AM
Roche Holdings (RHHBY) CEO Severin Schwan on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaRoche Holding's (RHHBY) CEO Severin Schwan on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 2 at 9:47 AM
China is a 'big focus' for Roche, CEO saysChina is a 'big focus' for Roche, CEO says
finance.yahoo.com - February 1 at 3:51 PM
Roche Holding AG to Host Earnings CallRoche Holding AG to Host Earnings Call
finance.yahoo.com - February 1 at 9:50 AM
U.S. tax change to help Roches 2018 profit growth outpace salesU.S. tax change to help Roche's 2018 profit growth outpace sales
finance.yahoo.com - February 1 at 9:50 AM
China is a big focus for Roche, CEO saysChina is a 'big focus' for Roche, CEO says
finance.yahoo.com - February 1 at 9:50 AM
Merus' Antibody Candidate in Phase II Breast Cancer StudyMerus' Antibody Candidate in Phase II Breast Cancer Study
finance.yahoo.com - January 29 at 3:52 PM
Roche wins FDAs breakthrough therapy label for autism drugRoche wins FDA's breakthrough therapy label for autism drug
finance.yahoo.com - January 29 at 9:58 AM
Roche (RHHBY) Scheduled to Post Quarterly Earnings on ThursdayRoche (RHHBY) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - January 25 at 2:24 AM
What You Need to Know About Puma Biotechs 25% SlideWhat You Need to Know About Puma Biotech's 25% Slide
www.msn.com - January 24 at 4:03 PM
Roche chairman: Business is in a healthy situationRoche chairman: Business is in a healthy situation
finance.yahoo.com - January 23 at 5:15 PM
Abcam signs licensing deal with Roche; shares riseAbcam signs licensing deal with Roche; shares rise
finance.yahoo.com - January 22 at 9:22 AM
Why Opdivo Could Continue to Be Growth Driver beyond 2018Why Opdivo Could Continue to Be Growth Driver beyond 2018
finance.yahoo.com - January 18 at 11:53 AM
BioLineRx Cancer Drug Positive as Monotherapy in Phase IIaBioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
finance.yahoo.com - January 18 at 11:53 AM
How Opdivo Is Positioned at the Beginning of 2018How Opdivo Is Positioned at the Beginning of 2018
finance.yahoo.com - January 18 at 9:11 AM
How Amgen’s Biosimilars Are Positioned for 2018How Amgen’s Biosimilars Are Positioned for 2018
finance.yahoo.com - January 18 at 9:10 AM
Exelixis, Ipsen Report Positive Results on Lead Cancer Drug - NasdaqExelixis, Ipsen Report Positive Results on Lead Cancer Drug - Nasdaq
www.nasdaq.com - January 17 at 11:24 AM
Roche launches CE-marked VENTANA MMR IHC Panel for patients diagnosed with colorectal cancerRoche launches CE-marked VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer
finance.yahoo.com - January 16 at 3:32 PM
Merck leaps past rivals with latest lung cancer drug resultsMerck leaps past rivals with latest lung cancer drug results
finance.yahoo.com - January 16 at 3:32 PM
Dow's Merck Does An About-Face, Releases Cancer Trial ResultsDow's Merck Does An About-Face, Releases Cancer Trial Results
finance.yahoo.com - January 16 at 3:32 PM
Will Amgen (AMGN) Continue to Tread Growth Path This Year?Will Amgen (AMGN) Continue to Tread Growth Path This Year?
finance.yahoo.com - January 16 at 10:47 AM
Roche (RHHBY) Downgraded by Societe GeneraleRoche (RHHBY) Downgraded by Societe Generale
www.americanbankingnews.com - January 15 at 9:40 AM
Your Daily Pharma Scoop: Roche Highlights Pipeline, GenSight Gets Nod To Start Trial, Bluebird Presents At JPM - Seeking AlphaYour Daily Pharma Scoop: Roche Highlights Pipeline, GenSight Gets Nod To Start Trial, Bluebird Presents At JPM - Seeking Alpha
seekingalpha.com - January 12 at 4:05 PM
What to Expect from Roche’s Tecentriq and Avastin in 2018What to Expect from Roche’s Tecentriq and Avastin in 2018
finance.yahoo.com - January 11 at 9:09 AM
Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018
finance.yahoo.com - January 10 at 3:33 PM
Ignyta’s Drug PipelineIgnyta’s Drug Pipeline
finance.yahoo.com - January 9 at 6:06 PM
Roche Holding Ltd. (RHHBY) Receives Average Rating of "Hold" from BrokeragesRoche Holding Ltd. (RHHBY) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 9 at 6:02 PM
GE Healthcare Partners Roche for Improved Critical Care - NasdaqGE Healthcare Partners Roche for Improved Critical Care - Nasdaq
www.nasdaq.com - January 9 at 10:38 AM

SEC Filings

Roche (OTCMKTS:RHHBY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Roche (OTCMKTS RHHBY) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.